J

JiangXi Tianxin Pharmaceutical Co Ltd
SSE:603235

Watchlist Manager
JiangXi Tianxin Pharmaceutical Co Ltd
SSE:603235
Watchlist
Price: 25.8 CNY -2.09% Market Closed
Market Cap: ¥11.3B

P/FCFE

341.7
Current
853%
More Expensive
vs 3-y average of 35.8

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
341.7
=
Market Cap
¥11.8B
/
Free Cash Flow to Equity
¥33.1m

Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.

P/FCFE
341.7
=
Market Cap
¥11.8B
/
Free Cash Flow to Equity
¥33.1m

Valuation Scenarios

JiangXi Tianxin Pharmaceutical Co Ltd is trading above its 3-year average

If P/FCFE returns to its 3-Year Average (35.8), the stock would be worth ¥2.71 (90% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-92%
Maximum Upside
No Upside Scenarios
Average Downside
90%
Scenario P/FCFE Value Implied Price Upside/Downside
Current Multiple 341.7 ¥25.8
0%
3-Year Average 35.8 ¥2.71
-90%
5-Year Average 40.7 ¥3.07
-88%
Industry Average 37.1 ¥2.8
-89%
Country Average 26.4 ¥1.99
-92%

Forward P/FCFE
Today’s price vs future free cash flow to equity

Not enough data available to calculate forward P/FCFE

Peer Comparison

All Multiples
P/FCFE
P/E
All Countries
Close
P/E Multiple
Earnings Growth PEG
CN
J
JiangXi Tianxin Pharmaceutical Co Ltd
SSE:603235
Average P/E: 7 099.8
18.3
N/A N/A
US
G
GE Vernova LLC
NYSE:GEV
Not Available
19%
N/A
UK
E
Eight Capital Partners PLC
F:ECS
Not Available N/A N/A
US
C
China Industrial Group Inc
OTC:CIND
4 020.7
N/A N/A
NL
N
Nepi Rockcastle NV
JSE:NRP
10.4
1%
10.4
US
F
Fintech Ecosystem Development Corp
NASDAQ:FEXD
38 368.9
N/A N/A
US
C
CoreWeave Inc
NASDAQ:CRWV
Not Available N/A N/A
CH
G
Galderma Group AG
SIX:GALD
Not Available
47%
N/A
US
Coupang Inc
F:788
173.5
96%
1.8
US
Symbotic Inc
NASDAQ:SYM
Negative Multiple: -3 256.9 N/A N/A
ZA
V
Vukile Property Fund Ltd
JSE:VKE
6.9
-5%
N/A

Market Distribution

Higher than 94% of companies in China
Percentile
94th
Based on 5 086 companies
94th percentile
341.7
Low
0.2 — 13.7
Typical Range
13.7 — 52.8
High
52.8 —
Distribution Statistics
China
Min 0.2
30th Percentile 13.7
Median 26.4
70th Percentile 52.8
Max 2 279 450.9

JiangXi Tianxin Pharmaceutical Co Ltd
Glance View

Market Cap
11.3B CNY
Industry
N/A

Perched in the vibrant province of Jiangxi, China, JiangXi Tianxin Pharmaceutical Co., Ltd. has carved a niche for itself as a formidable player in the pharmaceutical industry. Established with a clear vision to fuse traditional Chinese medicine with state-of-the-art technological advancements, the company specializes in the development and production of high-quality pharmaceutical products. JiangXi Tianxin's journey is a testament to its commitment to providing effective health solutions, emphasizing the importance of research and development to foster innovation within its product lines. The company operates with a holistic perspective, aiming to address various health concerns by integrating traditional wisdom with modern pharmaceutical practices. At the heart of its operations, JiangXi Tianxin's business model thrives on a diversified product portfolio, which spans active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. This strategic diversification allows the company to mitigate risks associated with market fluctuations while tapping into multiple revenue streams. By focusing on the production of APIs, JiangXi Tianxin ensures a robust supply chain necessary for developing essential medicines. Furthermore, its ability to manufacture a broad spectrum of products facilitates profitability through an economy of scale, allowing the company to maintain competitive pricing. By aligning its operational strategies with market demand and regulatory standards, JiangXi Tianxin not only sustains its growth but also fortifies its standing as a trusted pharmaceutical entity in both domestic and international markets.

Intrinsic Value
16.15 CNY
Overvaluation 37%
Intrinsic Value
Price ¥25.8
J
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett